

Oct 4 at 5:09 PM

FLGR-242 and alpha-Klotho-LR Product Update

Speakers: Jay Campbell, Michael Farber

Summary:

Executive Summary

- **Product pricing for FLGR242 and Klotho was permanently lowered to \$299 retail** for two vials, with **Jay** offering an affiliate discount code (JAYC) providing 20% off for the next 48 hours to bring the cost to \$239.
- **Initial swine gestational study results showed FLGR242 has an 8- to 9-day half-life** and increased piglet weight by 22% to 23% over placebo when dosed in sows during the last 40 days of gestation, with no observed heart enlargement.
- **Bioline 4 Extended Release is targeted to launch between October 20 and November 1**, featuring an apelin-13 long-release construct that achieves a 19-day half-life through albumin binding.
- **Human studies for FLGR242 and Klotho are expected to begin within one to two months** as institutional review boards request additional data, with initial trial readouts anticipated within six to seven months.

Full Summary

FLGR242 Research and Administration Protocols

- Initial results from a swine gestational study conducted in China demonstrated that FLGR242 has a half-life of 8 to 9 days, matching the literature-predicted half-life for albumin.
 - Sows dosed during the last 40 days of gestation delivered piglets with an average weight gain of 22% to 23% compared to placebo, showing no enlargement of the heart or negative health effects on sows or offspring.
 - **Michael Farber** noted this gestational element could be applied across other mammals, including equines, canines, and felines.
- Clinical dosing in humans for both FLGR242 and Klotho has proceeded slowly while awaiting IRB board approvals for additional data.

- Additional human studies are planned within one to two months, with trial readouts expected within six to seven months.
- A planned long-term obesity study spanning 28 to 52 weeks will examine caloric intake, lean mass, and muscle accretion alongside GLP-1 or GLP-2 compounds.
- **Michael Farber** addressed mechanism of action and cardiovascular safety, stating FLGR242 is a selective myostatin inhibitor derived from truncated follistatin that avoids the activin receptor complications and heart enlargement observed in drugs like Regeneron's garetosmab.
 - In comparison to Regeneron's trevogrumab and Eli Lilly's bimagrumab, FLGR242 directly blocks myostatin's braking effect on muscle growth rather than causing receptor desensitization or broad activin inhibition.
 - Investigational sublingual formulations are being evaluated, with **Michael Farber** estimating a potential 30% to 40% bioavailability compared to a standard 1% uptake typical of oral peptide delivery.
- Dosage guidelines and cycling recommendations were outlined by **Michael Farber** and **Jay** based on personal experimentation.
 - **Michael Farber** observed no incremental benefits above 7 to 7.5 milligrams per week for individuals weighing 200 to 220 pounds, suggesting a hard ceiling of 10 milligrams per week for individuals around 300 pounds.
 - **Jay** reported administering 2.5 milligrams three times per week before lifting sessions, totaling 7.5 milligrams weekly.
 - Users can cycle off FLGR242 for one to two months without losing lean muscle mass or strength due to its extended half-life.
 - Mild side effects such as muscle spasms or aches may occur at high dosages (e.g., 20 milligrams weekly) or in individuals with lower baseline muscle mass due to increased myokines.

Klotho Health Impacts and Clinical Regimens

- Klotho administration targets cardiovascular health, vascular endothelial function, nitric oxide release, and kidney function.

- **Michael Farber** reported that an 18-month regimen consisting of TRT, FLGR242, and Klotho brought personal blood pressure to 120/68, HbA1c to 4.9, and normalized lipid profiles.
- Klotho helps reverse renal fibrosis, proteinuria, and stage 3B chronic kidney disease in documented models by aiding the excretion of phosphates and excess minerals, though it cannot resuscitate dead nephrons.
- **Michael Farber** raised their personal estimated glomerular filtration rate (eGFR) from below 66 to 79 despite living with a single kidney, noting other users reached levels up to 109.
- Clinical administration typically follows a biweekly dosing schedule, taking four to six months to manifest noticeable improvements in eGFR and blood pressure.
 - If eGFR fails to improve, **Michael Farber** recommends tapering dosing intervals to every 13, 12, or 11 days until metrics normalize, after which patients can return to a 14-day interval.
 - For post-surgical patients, **Michael Farber** advised starting with a conservative half-dose of 5 micrograms every two weeks due to increased vascular blood flow.
 - Standard injection guidance includes subcutaneous administration at a 45-degree angle using warmed liquid limited to 0.75 mL to minimize injection site tenderness.

Bioline 4 Extended Release and Pipeline Developments

- Bioline 4 Extended Release (ER) is scheduled for commercial release between October 20 and November 1.
 - The compound targets four metabolic activators and incorporates apelin-13 long-release (LR).
 - The formula utilizes a proprietary albumin-binding construct incorporating a hydrophilic linker and SA21 across non-synthetic, natural amino acids, providing a 19-day half-life.
 - Patent 12,377,158 covers the fermentation expression process across cell lines for roughly 180 designed molecules.

- Clinical experiences from an initial 50-person user trial revealed enhanced thermogenesis and metabolic output during cardio without elevated heart rate, alongside appetite suppression at a dose of 32 micrograms per week.
 - Adverse effects were limited to isolated reports of loose stool and restless sleep, without nausea or vomiting.
 - Recommended titration begins across three to four weeks (20, 25, then 30 micrograms) before transitioning from weekly to biweekly administration, with one vial providing five to eight weeks of dosing.
 - A standalone apelin product is projected to release in three to four months.
- Pipeline updates include long-acting thymosin beta-4 and thymosin alpha constructs.
 - Thymosin beta-4 is designed to act synergistically with FLGR242 by reducing muscular inflammation and aiding tissue repair while FLGR242 stimulates stem cell hypertrophy.
 - Thymosin alpha is in development to restore immune system function counteracting age-related thymic atrophy.

Pricing and Commercial Updates

- Retail pricing for two vials of either FLGR242 or Klotho is set at \$299 permanently on biolongevitylabs.com.
- **Jay** announced that affiliate code JAYC yields a 20% discount (reducing the price to \$239) for the next 48 hours, while standard affiliate codes maintain a 15% discount.
- Pricing details for the upcoming Bioline 4 ER will be released in the coming weeks.